Skip to main content
S 754 107th Congress Senate Commerce Administrative procedure Antitrust law Civil Rights and Liberties, Minority Issues Civil actions and liability Drug approvals Drug industry Federal Trade Commission Fines (Penalties) Freedom of information Generic drugs Government Operations and Politics Government paperwork Health Independent regulatory commissions Injunctions Law Marketing Pharmaceutical research Research and development

Drug Competition Act of 2001

Introduced: April 6, 2001 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 107th Congress ended
It never became law before the 107th Congress (2001–2002) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 14 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 22, 2002
Referred to the Subcommittee on Health.
Nov 19, 2002
Message on Senate action sent to the House.
Nov 19, 2002
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Nov 19, 2002
Received in the House.
Nov 18, 2002
The committee substitute as amended agreed to by Unanimous Consent.
Nov 18, 2002
Passed Senate with an amendment by Unanimous Consent. (text: CR S11341-11342)
Nov 18, 2002
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text: CR S11341-11342)
Nov 18, 2002
Measure laid before Senate by unanimous consent. (consideration: CR S11339-11342; text of measure as reported in Senate: CR S11339-11340)
Jun 20, 2002
Placed on Senate Legislative Calendar under General Orders. Calendar No. 431.
Jun 20, 2002
Committee on the Judiciary. Reported by Senator Leahy with an amendment in the nature of a substitute. With written report No. 107-167.
Oct 18, 2001
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Apr 6, 2001
Introduced in Senate
Apr 6, 2001
Read twice and referred to the Committee on the Judiciary.
Apr 6, 2001
Sponsor introductory remarks on measure. (CR S3760-3761)
 Amendments to this bill 1

Amendments propose changes to this bill. Members vote on amendments separately before the final bill vote. An agreed amendment becomes part of the bill; a failed amendment does not.

1 agreed to

AmendmentSponsorPurposeStatusLatest action
SAMDT 4,965 — To make certain technical amendments. Agreed to Nov 18, 2002
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service
Drug Competition Act of 2001 - Requires a generic drug applicant that has submitted an Abbreviated New Drug Application (ANDA), and a brand name drug company, that enter into an agreement, prior to the generic drug entering the market, regarding the manufacture, marketing, or sale of the brand name or the generic drug, or regarding the 180-day semi-exclusivity period referred to in the Federal Food, Drug, and Cosmetic Act as it applies to such ANDA or any other ANDA based on the same brand name drug, to each file such agreement and any related agreements with the Assistant Attorney General and the Federal Trade Commission (FTC). Makes an exception for agreements that solely concern purchase orders for raw material supplies, equipment and facility contracts, or employment or consulting contracts. Requires such agreements to be filed not later than ten business days after the date they are executed.

Exempts any such information or documentary material filed from disclosure under the Freedom of Information Act. Prohibits such information or material from being made public, except as relevant to any administrative or judicial action or proceeding.

Subjects an applicant or company to a civil penalty of up to $11,000 for each day such entity fails to comply with this Act, recoverable in a civil action brought by the United States or the FTC. Authorizes the U.S. district court to order compliance and grant equitable relief, including rendering an agreement unenforceable for the period during which it was not filed as required.

What's happening now November 22, 2002

Referred to the Subcommittee on Health.

 Bill text 4 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 4
All 4 Democratic 3 Republican 1
R
Grassley, Chuck
Iowa · Jun 21, 2002
 D
Cantwell, Maria
Washington · Jul 9, 2001
 D
Durbin, Richard J.
Illinois · Apr 6, 2001
 D
Schumer, Charles E.
New York · Apr 6, 2001
Cite this page click to expand
APA
U.S. Congress. (2026). S. 754: Drug Competition Act of 2002. 107th Congress. Open America. https://openamerica.io/bill/107-S-754/
MLA
"S. 754: Drug Competition Act of 2002." 107th Congress, 2026, Open America, https://openamerica.io/bill/107-S-754/.
Bluebook (legal)
S. 754, 107th Cong. (2026), https://openamerica.io/bill/107-S-754/.
Markdown link
[S. 754: Drug Competition Act of 2002](https://openamerica.io/bill/107-S-754/)
Report a problem